Learning curve and stage migration of a radical retropubic prostatectomy series over a 10-y period

Prostate Cancer and Prostatic Diseases

Volumn 7, Issue 3, 2004, Pages 258-262

  Winkler, M H ^a,b   Gillatt, D A ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Prostate; Prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BLOOD TRANSFUSION; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OPERATION DURATION; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SURGICAL TECHNIQUE; TREATMENT OUTCOME; UNITED KINGDOM; BLOOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; SURVIVAL RATE;

AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 16644370989     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500734     Document Type: Article

References (23)

1. Ohori M et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152: 1843-1849.
2. Paulson DF. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994; 152: 1826-1830.
3. Kupelian P et al. Correlation of clinical and pathological factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996; 48: 246-260.
4. Zietman AL et al. Radical prostatectomy for adenocarcinoma of the prostate: The influence of preoperative and pathological findings on biochemical disease-free outcome. Urology 1994; 43: 828-833.
5. Walsh PC, Partin AW, Ebstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol 1994; 152: 1831-1836.
6. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994; 152: 1821-1825.
7. Dillioglugil O et al. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 1997; 50: 93-99.
8. Oliver SE et al. Recent trends in the use of radical prostatectomy in England: The epidemiology of diffusion. BJU Int 2003; 91: 331-336, (discussion 336).
9. Collett D. Modelling Survival Data in Medical Research. Chapman & Hall: London, 1994.
10. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515-526.
11. Litwiller SE et al. Radical retropubic prostatectomy for localized carcinoma of the prostate in a large metropolitan hospital: Changing trends over a 10-year period (1984-1994). Dallas Outcomes Research Group for Urological Disorders. Urology 1995; 45: 813-822.
12. Moul JW et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: An overview of the Department of Defense Center for Prostate Disease Research national database. Surgery 2002; 132: 213-219.
13. Freedland SJ et al. Time trends in biochemical recurrence after radical prostatectomy: Results of the SEARCH database. Urology 2003; 61: 736-741.
14. Ung JO et al. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002; 60: 458-463.
15. D'Amico AV et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002; 95: 281-286.
16. Han M et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 517-523.
17. Catalona WJ, Ramos CG, Carvalhal GF. Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin 1999; 49: 282-296.
18. Hull GW et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167 (2 Part 1): 528-534.
19. Melia J, Moss S. Survey of the rate of PSA testing in general practice. Br J Cancer 2001; 85: 656-657.
20. Hu JC et al. Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol 2003; 21: 401-405.
21. Ellison LM, Heaney JA, Birkmeyer JD. The effect of hospital volume on mortality and resource use after radical prostatectomy. J Urol 2000; 163: 867-869.
22. Yao SL, Lu-Yao G. Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay. J Natl Cancer Inst 1999; 91: 1950-1956.
23. Holmberg L et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781-789.